

June 14, 2013

AbbVie GK

[Notes to editors]

1. HUMIRA® Pre-filled Syringe 40 mg / 0.8 mL product outline (new prescription information underlined)

1) Indications

Rheumatoid arthritis (including inhibition of structural damage)

Patients who have had an inadequate response to conventional therapy for the following diseases:

Plaque psoriasis and psoriatic arthritis

Ankylosing spondylitis

Juvenile idiopathic arthritis with active polyarthritis

Intestinal Behçet's disease

Induction and maintenance therapy for moderate to severely active Crohn's disease (restricted to patients who have had an inadequate response to conventional therapy)

Treatment of moderate to severe ulcerative colitis (restricted to patients who have had an inadequate response to conventional therapy)

2) Dosage and administration

Rheumatoid arthritis

The dose of adalimumab (recombinant) for adult patients is 40 mg administered every other week (eow) as a subcutaneous injection. The dose may be increased to 80 mg administered eow when the effect of treatment with 40 mg eo

Disease Treatment Research Program) amounts to more than 130,000 and this figure increases every year by approximately 8,000 cases¹.

2) TNF-

The tumor necrosis factors (TNFs) are a group of cytokines mediating intercellular communication that have been found to damage tumor cells. TNF-